Cartalax

Cartalax is a synthetic tripeptide (Ala-Glu-Asp) claimed to support cartilage health. Developed in Russia as part of the Khavinson peptide series. Very limited published data.

PubMed results: 0 · Human studies: 0 · Animal studies: 0

Ranges reflect protocols studied in published research and animal-model extrapolation. Presented for research purposes only, not a recommendation or instruction for human use.

Doses studied in published research. Information presented for research purposes only, not a recommendation for human use.

• Not established — standard range No established dosing, Not established. Very limited published primary research on Cartalax dose, route, or schedule. No established human protocol; claims in commercial materials are not a substitute for controlled trial data.

Not established in humans (theoretical confidence)

Synthetic tripeptide (Ala-Glu-Asp) in the Khavinson cytomedin series. No reliable peer-reviewed human or animal PK half-life identified in accessible literature.

• Cartilage tissue research interest (Limited): Cartalax (Ala-Glu-Asp) is described in Khavinson peptide literature as a short synthetic tripeptide studied in relation to cartilage and connective-tissue homeostasis, though independent peer-reviewed human evidence remains sparse
• Bioregulatory peptide research framework (Theoretical): Research on the broader Khavinson short-peptide series frames Cartalax within tissue-specific bioregulatory hypotheses; published mechanistic and clinical detail for this specific tripeptide is very limited

• No documented human side effects in published literature — Mild, Not established. Very limited published clinical data means a formal adverse-event profile has not been established in the peer-reviewed literature

• Insufficient safety data in humans (Theoretical / Preclinical): Given the scarcity of controlled human trials, research settings generally treat Cartalax as lacking an established safety and contraindication profile

Lyophilized (powder): Refrigerated (2-8°C), Up to 24 months. Light sensitive: yes, store dark

Reconstituted (solution): Refrigerated (2-8°C), 4-6 weeks. Solvent: Bacteriostatic water

• NCT06852014 — Effects of Peptamen 1.6 in Malnourished Patients (or at Risk) With Pancreatic Neoplasia Undergoing Cephalic Pancreaticoduodenectomy (CPD): A Mechanistic Study (NA), status: RECRUITING. Indications: Pancreatic Cancer, Adult, Cephalic Duodenopancreatectomy

No PubMed-indexed primary literature was found for this compound at review time. Sections summarize commonly cited research context; treat as lower-confidence until citations are added.